Mains › Mains Hub
MainsPYQs2022 · GS IV · Q15

Dimension Map

I

Conflict between fiduciary duty to government and personal economic benefit

Tests whether candidate recognizes the asymmetric power relationship and the scientist's legal/moral obligation to the funding source that enabled the discovery

Example point Government bore the R&D risk and cost; private benefit from government-funded work raises questions of resource misappropriation and breach of trust
II

Institutional integrity vs. individual incentive alignment in scientific research

Explores whether research institutions can retain talent and credibility if scientists systematize extraction of commercial value from public projects, creating perverse incentives

Example point If tacitly permitted, other researchers may prioritize patentability over scientific rigor or public good research with lower commercial appeal
III

Procedural pathway and transparency in technology transfer vs. clandestine private negotiation

Distinguishes between legitimate IP commercialization frameworks (institutional tech transfer offices, benefit-sharing policies) and ethically compromised back-channel deals

Example point Many research institutions have formal IP policies; bypassing them for personal gain suggests intentional circumvention of governance safeguards
IV

Public interest in research outcomes and equitable access vs. proprietary capture

Questions whether discoveries funded by taxpayers should be locked into private control, particularly if the research has health, agricultural, or social applications

Example point A vaccine or diagnostic developed with government funds may serve public health better through open licensing than through exclusive private commercialization

Value-Add Radar

Factual

India's Department of Science and Technology guidelines on IP ownership (2018) explicitly state that inventions developed using government facilities and funds vest with the government institution, with provision for inventor monetary recognition capped at a percentage of licensing revenue, not personal direct payments from third parties.

Analytical

Most answers treat this as a simple conflict of interest; the deeper ethical issue is whether the scientist is instrumentalizing her position and institutional resources for personal enrichment, which corrodes the social contract underlying public research funding.

Contemporary

The 2023 National Research Foundation Act emphasized institutional technology transfer frameworks and benefit-sharing models, signaling government intent to formalize (not suppress) commercialization while maintaining public interest safeguards.

What to Avoid / What to Add

Cliché Trap

Aspirants typically frame this as a binary choice ('say yes and be greedy' vs. 'say no and be ethical') rather than advising the scientist to pursue institutional technology transfer with proper benefit-sharing, which would be the mature institutional response that respects both public interest and legitimate incentivization.

Temporal Anchor

Post-2022 policy emphasis on 'Atmanirbhar Bharat' and government push for R&D commercialization has created a false impression among some scientists that personal technology transfer is encouraged; the 2023 NRF Act clarified that institutional frameworks, not individual backdoor deals, are the legitimate pathway.

Cross-Node Alert

Civil service aptitude dimension matters because the response reveals whether the candidate would, as a director, enforce institutional norms, counsel the scientist through proper channels, or tacitly condone deviation—each reveals leadership integrity and institutional stewardship capacity.

Intro Frames

1.

This case presents a fundamental tension between the scientist's individual economic interest and her fiduciary obligation to the institution and public that funded her research, requiring the director to counsel a path that respects institutional integrity without denying legitimate commercialization.

2.

At its core, this dilemma tests whether publicly-funded discoveries can be ethically privatized through informal arrangements, or whether proper institutional mechanisms must mediate the transformation of government investment into commercial value.

Conclusion Frames

1.

The director's role is to channel the scientist's entrepreneurial instinct through formal technology transfer frameworks that ensure public interest protection, institutional credibility, and legitimate personal reward—rejecting the private company's approach not as a ban on commercialization, but as a redirection toward transparent governance.

2.

Advising the scientist to decline the private payment while facilitating institutional IP commercialization preserves both the scientist's career and the institution's integrity, transforming a potential ethical breach into a model of responsible innovation stewardship.

Ready to write?

Use the Mains Arena to practise this question with self-evaluation.

Open Arena →